Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
New 2025 to 2030 Dietary Guidelines for Americans shift focus to whole foods, full-fat dairy, and protein prioritization while targeting ultraprocessed products as chronic disease drivers